

Clinical trials of aliskiren

TrialResults-center www.trialresultscenter.org

1 hypertension

| Trial | Treatments | Patients | Trials design and methods |
|---|--|---|---|
| aliskiren vs amlodipine | | | |
| ACCELERATE , 2011 [NCT00797862] n=NA follow-up: | - | essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mmHg | |
| aliskiren vs placebo | | | |
| AVOID , 2008 [NCT00097955] n=301/298 follow-up: 6 months | aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months) versus placebo | patients with hypertension and type 2 diabetes with nephropathy | Parallel groups double blind 15 countries |
| aliskiren vs hydrochlorothiazide | | | |
| Schmieder (vs HCTZ) , 2009 n=567/557 follow-up: 20 weeks | aliskiren 300 mg versus hydrochlorothiazide 25 mg | patients with essential hypertension | Parallel groups double blind |
| aliskiren vs losartan | | | |
| ALLAY , 2009 [NCT00219141] n=154/152 follow-up: 9 months | aliskiren 300 mg versus losartan 100 mg | patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m ² | Parallel groups open |
| aliskiren vs ramipril | | | |
| Andersen , 2008 n=NA follow-up: 26 weeks | aliskiren 150 mg (up to 300mg) daily versus ramipril 5 mg (up to 10mg) daily | - | Parallel groups double blind |

More details and results :

- anti hypertensive agents for hypertension in diabetic patients at <http://www.trialresultscenter.org/go-Q10>
- anti hypertensive agents for hypertension in all type of patient at <http://www.trialresultscenter.org/go-Q13>
- anti hypertensive agents for hypertension in nephropathy at <http://www.trialresultscenter.org/go-Q19>

- renin inhibitor for hypertension in all type of patients at <http://www.trialresultscenter.org/go-Q309>
- renin inhibitor for hypertension in diabetic patients at <http://www.trialresultscenter.org/go-Q310>
- anti hypertensive agents for hypertension in uncomplicated hypertension at <http://www.trialresultscenter.org/go-Q685>
- anti hypertensive agents for hypertension in patients with additional risk factor at <http://www.trialresultscenter.org/go-Q686>

References

ACCELERATE, 2011:

Brown MJ, McInnes GT, Papst CC, Zhang J, Macdonald TM Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011 Jan 12;: [21236483] 10.1016/S0140-6736(10)62003-X

AVOID, 2008:

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46 [18525041]

Schmieder (vs HCTZ), 2009:

Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119:417-25 [19139391]

ALLAY, 2009:

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlf B Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-7 [19153265]

Andersen, 2008:

Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-99 [18300872]

2 heart failure

| Trial | Treatments | Patients | Trials design and methods |
|---|--------------------------------|---|--|
| Aliskiren vs placebo | | | |
| ASTRONAUT , 2013 [NCT00894387] n=1639 follow-up: 6 months | Aliskiren versus placebo | stable patients with heart failure, an LVEF <40% (mean 28%), and elevated natriuretic peptides who had been discharged from a heart-failure hospitalization an average of five days before | Parallel groups double blind North and South america, Europe, Asia |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|---------------------------------|
| aliskiren vs Enalapril | | | |
| ATMOSPHERE <i>ongoing</i> [NCT00853658] n=NA follow-up: | Aliskiren 150 mg titrated to 300 mg versus enalapril 10 mg | patients with chronic heart failure NYHA Class II - IV. | Parallel groups double blind |

More details and results :

- renin inhibitor for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q311>
- renin inhibitor for heart failure in acute decompensated heart failure at <http://www.trialresultscenter.org/go-Q319>

References

ASTRONAUT, 2013:

ATMOSPHERE, :

ongoing trial NCT00853658

McMurray JJ, Krum H, Abraham WT, Dickstein K, Kber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med 2016;374:1521-32 [27043774]

McMurray JJ, Krum H, Abraham WT, Dickstein K, Kber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med 2016;374:1521-32 [27043774]

Entry terms: CGP 060536B, CGP060536B, CGP-060536B, Tekturna, SPP100,